<?xml version="1.0" encoding="UTF-8" ?>

<Genomics_ConceptTask>
<TEXT><![CDATA[SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK 
Signaling Pathways.

The level of SETD2-mediated H3K36me3 is inversely correlated with that of 
EZH2-catalyzed H3K27me3. Nevertheless, it remains unclear whether these two 
enzymatic activities are molecularly intertwined. Here, we report that SETD2 
delays prostate cancer (PCa) metastasis via its substrate EZH2. We show that 
SETD2 methylates EZH2 which promotes EZH2 degradation. SETD2 deficiency induces 
a Polycomb-repressive chromatin state that enables cells to acquire metastatic 
traits. Conversely, mice harboring nonmethylated EZH2 mutant or SETD2 mutant 
defective in binding to EZH2 develop metastatic PCa. Furthermore, we identify 
that metformin-stimulated AMPK signaling converges at FOXO3 to stimulate SETD2 
expression. Together, our results demonstrate that the SETD2-EZH2 axis 
integrates metabolic and epigenetic signaling to restrict PCa metastasis.]]></TEXT>
<TAGS>
<PERTURBING_ACTION id="P0" spans="457~473" text="SETD2 deficiency" perturbingaction="gene loss-of-function" />
<PERTURBING_ACTION id="P1" spans="598~623" text="nonmethylated EZH2 mutant" perturbingaction="other" />
<PERTURBING_ACTION id="P2" spans="627~669" text="SETD2 mutant  defective in binding to EZH2" perturbingaction="other" />
<CONTEXT id="C0" spans="534~539" text="cells" context="cells" />
<CONTEXT id="C1" spans="583~587" text="mice" context="organism" />
<PHENOTYPE id="PH0" spans="551~569" text="metastatic  traits" phenotype="metastasis" />
<EFFECT id="E0" spans="543~550" text="acquire" effect="positive" />
<ENTITY_LINKING id="EN0" perturbing_actionID="P0" perturbing_actionText="SETD2 deficiency" contextID="C0" contextText="cells" effectID="E0" effectText="acquire" phenotypeID="PH0" phenotypeText="metastatic  traits" />
</TAGS>
</Genomics_ConceptTask>